Education
About Us
Working with TipRanks
Follow Us
Xoma Corp (XOMA)
NASDAQ:XOMA
XOMA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$18.35 - $35.00
Previous CloseN/A
Volume8.24K
Average Volume (3M)29.74K
Market Cap
$230.35M
Enterprise Value$324.15M
Total Cash (Recent Filing)$28.42M
Total Debt (Recent Filing)$13.34M
Price to Earnings (P/E)―
Beta0.75
Next Earnings
May 13, 2025EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.06
Shares Outstanding11,952,889
10 Day Avg. Volume24,371
30 Day Avg. Volume29,741
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)8.78
Price to Cash Flow (P/CF)-21.50
P/FCF Ratio0.00
Enterprise Value/Market Cap1.41
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit11.46
Enterprise Value/Ebitda-11.67
Forecast
1Y Price Target
$79.50Price Target Upside293.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
Xoma News
PremiumCompany Announcements
XOMA Royalty Reports Strong 2024 Financial Growth
PremiumPre-Earnings
Is XOMA a Buy, Before Earnings?
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceXOMA ended the year financially strong with $106.8 million in cash, balanced by growing revenues from royalties and milestones.
Revenue GrowthXOMA reported 4Q24 total revenue of $8.7M, 19% above the analyst estimate.
Royalty RevenueErsodetug offers XOMA a de-risked path to royalties in the CHI market, in our opinion.
Bears Say
Market PerceptionThe market under-appreciates XOMA’s long-term revenue potential from Vabysmo sales.
Price TargetThe price target has been reduced to $104 from $123, primarily based on the removal of iscalimab from projections.
---
Ownership Overview
1.53% Insiders
13.68% Mutual Funds
40.03% Other Institutional Investors
38.39% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
XOMA FAQ
What was Xoma Corp’s price range in the past 12 months?
Xoma Corp lowest stock price was $18.35 and its highest was $35.00 in the past 12 months.
What is Xoma Corp’s market cap?
Xoma Corp’s market cap is $230.35M.
When is Xoma Corp’s upcoming earnings report date?
Xoma Corp’s upcoming earnings report date is May 13, 2025 which is in 33 days.
How were Xoma Corp’s earnings last quarter?
Xoma Corp released its earnings results on Mar 17, 2025. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.287 by $0.247.
Is Xoma Corp overvalued?
According to Wall Street analysts Xoma Corp’s price is currently Undervalued.
Does Xoma Corp pay dividends?
Xoma Corp does not currently pay dividends.
What is Xoma Corp’s EPS estimate?
Xoma Corp’s EPS estimate is -0.26.
How many shares outstanding does Xoma Corp have?
Xoma Corp has 11,952,889 shares outstanding.
What happened to Xoma Corp’s price movement after its last earnings report?
Xoma Corp reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.287. Following the earnings report the stock price went up 0.772%.
Which hedge fund is a major shareholder of Xoma Corp?
Currently, no hedge funds are holding shares in XOMA
---
Xoma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$79.50 (293.76% Upside)
$79.50 (293.76% Upside)
Hedge Fund Trend
Increased
By 60.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $16.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.67%
12-Months-Change
Fundamentals
Return on Equity
-16.20%
Trailing 12-Months
Asset Growth
-3.13%
Trailing 12-Months
Company Description
Xoma Corp
XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
---
XOMA Stock 12 Month Forecast
Average Price Target
$79.50
▲(293.76% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Corcept Therapeutics
―
Madrigal Pharmaceuticals
―
GlycoMimetics
―
AnaptysBio
―
Best Analysts Covering XOMA
1 Year
1 Year Success Rate
5/17 ratings generated profit
1 Year Average Return
-4.81%
reiterated a buy rating 15 days ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 29.41% of your transactions generating a profit, with an average return of -4.81% per trade.
---